Harmony Biosciences Holdings (HRMY) Operating Income (2019 - 2026)

Harmony Biosciences Holdings' Operating Income history runs 8 years deep, the most recent figure standing at $8.3 million for Q1 2026.

• In Q1 2026, Operating Income fell 85.18% year-over-year to $8.3 million; the TTM figure through Mar 2026 stood at -$2.7 million (down 101.41% YoY), while the FY2025 annual figure was $45.2 million, down 76.33% from the prior year.
• Operating Income came in at $8.3 million for Q1 2026 at Harmony Biosciences Holdings, up from -$124.7 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of $65.5 million in Q3 2025 to a low of -$124.7 million in Q4 2025.
• A 5-year average of $32.7 million and a median of $46.9 million in 2023 frame the typical range for Operating Income.
• Across the five-year window, Operating Income surged 442.05% in 2023 and sank 323.86% in 2025, its largest moves.
• Harmony Biosciences Holdings' Operating Income stood at $47.6 million in 2022, then dropped by 15.58% to $40.2 million in 2023, then jumped by 38.64% to $55.7 million in 2024, then tumbled by 323.86% to -$124.7 million in 2025, then jumped by 106.68% to $8.3 million in 2026.
• According to Business Quant data, Operating Income over the past three periods registered $8.3 million, -$124.7 million, and $65.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison